E-viri
PDF
Recenzirano
Odprti dostop
-
Maghzi, Amir Hadi; Houtchens, Maria K.; Preziosa, Paolo; Ionete, Carolina; Beretich, Biljana D.; Stankiewicz, James M.; Tauhid, Shahamat; Cabot, Ann; Berriosmorales, Idanis; Schwartz, Tamara H. W.; Sloane, Jacob A.; Freedman, Mark S.; Filippi, Massimo; Weiner, Howard L.; Bakshi, Rohit
Journal of neurology, 10/2020, Letnik: 267, Številka: 10Journal Article
The outbreak of a severe acute respiratory syndrome caused by a novel coronavirus (COVID-19), has raised health concerns for patients with multiple sclerosis (MS) who are commonly on long-term immunotherapies. Managing MS during the pandemic remains challenging with little published experience and no evidence-based guidelines. We present five teriflunomide-treated patients with MS who subsequently developed active COVID-19 infection. The patients continued teriflunomide therapy and had self-limiting infection, without relapse of their MS. These observations have implications for the management of MS in the setting of the COVID-19 pandemic.
